This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Alkermes (ALKS) Reports Wider-Than-Expected Loss in Q1
by Zacks Equity Research
Alkermes (ALKS) posts wider than expected loss in the first quarter of 2018. However, sales beat estimates.
Shire (SHPG) Q1 Earnings Beat, Rare Disease Franchise Strong
by Zacks Equity Research
Shire (SHPG) reports better-than-expected first-quarter earnings and records strong growth in immunology franchise and newly launched products.
Vertex (VRTX) Q1 Earnings Beat on Strong CF Products Sales
by Zacks Equity Research
Vertex Pharma (VRTX) first-quarter earnings increase from the year-ago period led by strong sales trend of CF drugs.
Alexion's (ALXN) Earnings Beat Estimates in Q1, Guidance Up
by Zacks Equity Research
Alexion exceeds both earnings and sales expectations in the first quarter of 2018.The company also raised revenue and earnings guidance for 2018.
Catalyst Enrolls First Patient in Phase III Firdapse Study
by Zacks Equity Research
Catalyst (CPRX) enrolls the first patient in its phase III clinical trial (MSK-002) to evaluate the efficacy and safety of Firdapse in patients with MuSK antibody positive Myasthenia Gravis.
Bayer to Divest 3.6% Stake to Singapore Company Temasek
by Zacks Equity Research
Bayer (BAYRY) will divest its 3.6% stake to Singapore's state investment company Temasek for total gross proceeds of ???3 billion.
U.S. Markets Close Highest in a Month: 4 Momentum Picks
by Nalak Das
Stock market momentum will persist as first-quarter earnings have so far have been better than expected and several big companies are yet to release results.
Alnylam (ALNY) Reports Positive Data for RNAi Candidate
by Zacks Equity Research
Alnylam (ALNY) announced encouraging results from phase I and phase I/II open-label extension studies of givosiran, which is being evaluated for the treatment of acute hepatic porphyrias.
Alkermes Rallies as FDA Accepts NDA for Depression Drug
by Zacks Equity Research
Shares of Alkermes (ALKS) rose when the FDA accepted for review the new drug application for its depression candidate ALKS 5461 two weeks after it had issued a Refusal to File letter.
Intercept Reports Phase III Sub-Study Liver Biopsy Data
by Zacks Equity Research
Intercept (ICPT) announces data from the POISE biopsy sub-study which showed that treatment with obeticholic acid leads to the reversal or stabilization of fibrosis/cirrhosis in patients with primary biliary cholangitis.
Here's Why Geron Stock Surged More Than 90% in 6 Months
by Zacks Equity Research
Geron (GERN) telomerase inhibitor, imetelstat, is being evaluated in two late stage studies. The candidate is progressing well in the Janssen sponsored studies.
Protagonist Therapeutics (PTGX) Enters Oversold Territory
by Zacks Equity Research
Protagonist Therapeutics, Inc. (PTGX) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock
FDA Lifts Clinical Hold on Bellicum's (BLCM) T Cell Therapy
by Zacks Equity Research
Bellicum (BLCM) agrees to make amendments to the protocols relating to clinical studies evaluating its T Cell Therapy, BPX-501.
Epizyme (EPZM) Publishes Tazemetostat Phase I Data, Stock Up
by Zacks Equity Research
Epizyme (EPZM) publishes tazemetostat phase I clinical data in The Lancet Oncology. The study demonstrated favorable safety findings and anti-tumor activity.
Spectrum Pharma Stock Up on Positive Lung Cancer Study Data
by Zacks Equity Research
Spectrum Pharmaceuticals' (SPPI) poziotinib shows encouraging results in preliminary analysis of data from phase II lung cancer study.
The Zacks Analyst Blog Highlights: Verona, Squibb, Protagonist and Amgen
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Verona, Squibb, Protagonist and Amgen
Protagonist Therapeutics Stalls Ulcerative Colitis Study
by Zacks Equity Research
Protagonist Therapeutics' (PTGX) shares plunge more than 50%, following discontinuation of a mid-stage study on its key ulcerative colitis candidate, PTG-100.
Why Global Blood Therapeutics (GBT) Could Be Positioned for a Slump
by Zacks Equity Research
It seems to be a wise decision for investors to drop Global Blood Therapeutics (GBT) stock considering its negative estimate revision, price depreciation as well as unfavorable Zacks rank.
BioDelivery Sciences (BDSI) in Focus: Stock Moves 5.1% Higher
by Zacks Equity Research
Shares of BioDelivery Sciences (BDSI) rose over 5% yesterday.
Geron (GERN) in Focus: Stock Moves 10.8% Higher
by Zacks Equity Research
Geron (GERN) was a big mover last session, as the company saw its shares rise nearly 11% on the day.
G1 Therapeutics (GTHX) in Focus: Stock Moves 8.9% Higher
by Zacks Equity Research
Shares of G1 Therapeutics (GTHX) rose nearly 9% yesterday.
BioTime, Inc. (BTX) Looks Good: Stock Adds 6% in Session
by Zacks Equity Research
BioTime (BTX) was a big mover last session, as the company saw its shares rise 6% on the day amid huge volumes.
Penumbra (PEN) Forms JV on Virtual Reality in Health Space
by Zacks Equity Research
Penumbra's (PEN) joint venture with Sixense Enterprises indicates formation of a leading digital health platform in the field of virtual reality technology.
New Products Aid Boston Scientific, LOTUS Relaunch Lag Ails
by Zacks Equity Research
Boston Scientific (BSX) grows on product launches and international expansion. LOTUS relaunch delay hurts sales.
Thermo Fisher Buys Phenom-World, Aids Analytical Instruments
by Zacks Equity Research
On completion of Phenom-World purchase, Thermo Fisher (TMO) plans to integrate the business into its Analytical Instruments segment.